Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

13.83
+1.209.50%
Post-market: 13.81-0.0217-0.16%19:39 EDT
Volume:3.68M
Turnover:50.61M
Market Cap:1.09B
PE:6.53
High:14.19
Open:13.09
Low:13.01
Close:12.63
52wk High:17.29
52wk Low:5.70
Shares:78.65M
Float Shares:72.22M
Volume Ratio:2.42
T/O Rate:5.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.12
EPS(LYR):1.87
ROE:82.56%
ROA:2.29%
PB:4.69
PE(LYR):7.40

Loading ...

FDA-Approved PD-L1 Test for GI Cancers Could Be A Game Changer For Agilent Technologies (A)

Simply Wall St.
·
Jul 19

Pagerduty Director Alex Shootman Files Initial Beneficial Ownership Statement

Reuters
·
Jul 16

SKB BIO's Pivotal Drug Candidate Achieves Primary Endpoint in Phase 3 Lung Cancer Trial

Stock News
·
Jul 15

Pagerduty Names Alkami CEO Alex Shootman to Board of Directors

Reuters
·
Jul 15

Pagerduty Appoints Alex Shootman to Board of Directors

THOMSON REUTERS
·
Jul 15

Agilent's PD-L1 Companion Diagnostic Receives FDA Clearance for Esophageal and Gastric Cancer Immunotherapy Selection

Deep News
·
Jul 14

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

GlobeNewswire
·
Jul 14

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

GlobeNewswire
·
Jul 14

Truist Financial Keeps Their Buy Rating on PagerDuty (PD)

TIPRANKS
·
Jul 14

Pagerduty Names Arnaud Lagarde Vice President of EMEA

Reuters
·
Jul 14

Pagerduty Announces Arnaud Lagarde, Vice President of Emea

THOMSON REUTERS
·
Jul 14

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

GlobeNewswire
·
Jul 12

LEADS BIOLABS-B's Novel Cancer Therapy LBL-024 Granted Priority Review in China for Advanced Neuroendocrine Carcinoma

Stock News
·
Jul 10

Pagerduty is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 09

PagerDuty price target raised to $11 from $9 at Truist

TIPRANKS
·
Jul 09

Truist Securities Adjusts Price Target on PagerDuty to $11 From $9, Maintains Buy Rating

MT Newswires Live
·
Jul 09

Shandong Boan Wins CDE Nod for Next-Gen PD-1/IL-2 Cancer Drug BA1203

TIPRANKS
·
Jul 08

Pagerduty Files Form 3 Beneficial Ownership Statement for CFO Eric Prengel

Reuters
·
Jul 07

ABBISKO-B Unit Enters Strategic Collaboration with AstraZeneca for Clinical Study on First-in-Class Oral PD-L1 Inhibitor Combined with Tagrisso in Non-Small Cell Lung Cancer

Stock News
·
Jul 02

Press Release: Annovis Appoints Cheng Fang, Ph.d., as Chief Scientific Officer

Dow Jones
·
Jul 01